---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-148853"
form_type: "8-K"
ticker: "OFIX"
cik: "0000884624"
company_name: "Orthofix Medical Inc."
filed_at: "2026-04-09T23:59:59+00:00"
generated_at: "2026-05-15T06:51:36.784304+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Orthofix reports prelim Q1 net sales $196.7M, realigns spine leadership, Reinhardt to depart

## Summary
- Preliminary Q1 net sales $196.7M; reported constant currency +0.4%, pro forma constant currency +2.7% YoY.
- FY 2026 guidance reaffirmed: net sales $850M-$860M, adj. EBITDA $95M-$98M, positive FCF ex-legal settlements.
- President, Global Spine Max Reinhardt to depart on/about June 12, 2026; role eliminated in realignment.
- Key spine leaders (Bannigan, Sienkiewicz, Winge) now report directly to CEO; Fisher expands to Biologics.
- M6 disc discontinuation impact fell to $0.3M in Q1 from $4.4M in Q1 2025.

## SEC filing metadata
- accession: 0001193125-26-148853
- form_type: 8-K
- ticker: OFIX
- cik: 0000884624
- company_name: Orthofix Medical Inc.
- filed_at: 2026-04-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/884624/000119312526148853/0001193125-26-148853-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/884624/000119312526148853/ofix-20260409.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-148853
- JSON: https://secwatch.observer/filing/0001193125-26-148853.json
- Plain text: https://secwatch.observer/filing/0001193125-26-148853.txt

## Key facts
- Earnings Releases
  Orthofix Medical Inc. reported full-year 2026 results: revenue $850 million to $860 million. Guidance reaffirmed.
  - Period: full-year 2026
  - Revenue: $850 million to $860 million
  - Guidance: reaffirmed
  - Result: guidance update
  source text: The company also reaffirmed its full-year 2026 guidance as follows: • Net sales expected to range between $850 million to $860 million. The Company’s expected net sales represent implied year-over-year pro forma constant currency growth of approximately 5.5% at the midpoint of the range. This guidance range is based on current foreign currency exchange rates and does not take into account any additional potential exchange rate changes that may occur this year. • Non-GAAP adjusted EBITDA expected to be $95 million to $98 million. This represents 70 basis points of non-GAAP adjusted EBITDA margin expansion at the midpoint of the range compared to 2025. • Free cash flow expected to be positive for full-year 2026, excluding the impact of any potential legal settlements.
  evidence_url: https://www.sec.gov/Archives/edgar/data/884624/000119312526148853/0001193125-26-148853-index.htm
- Earnings Releases
  Orthofix Medical Inc. reported first quarter ended March 31, 2026 results: revenue $196.7 million.
  - Period: first quarter ended March 31, 2026
  - Revenue: $196.7 million
  - Result: preliminary results
  source text: Orthofix today reported preliminary, unaudited first quarter 2026 net sales of approximately $196.7 million, including sales from M6 artificial cervical and lumbar discs, and non-GAAP pro forma net sales of approximately $196.4 million, excluding sales from M6 discs, representing an increase of 0.4% on a reported basis and 3% on a non-GAAP pro forma constant currency basis compared to Q1 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/884624/000119312526148853/0001193125-26-148853-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.